Treatment of dyslipidemia: we don't know all we think we know.
作者信息
LeLorier Jacques
出版信息
Can J Cardiol. 2006 Jul;22(9):737-8. doi: 10.1016/s0828-282x(06)70288-4.
Abstract
摘要
相似文献
1
Treatment of dyslipidemia: we don't know all we think we know.血脂异常的治疗：我们所知道的并非如我们自以为知道的那般全面。
Can J Cardiol. 2006 Jul;22(9):737-8. doi: 10.1016/s0828-282x(06)70288-4.
2
Reducing cardiovascular risk and managing dyslipidemia in women.
Nurs Womens Health. 2007 Dec;11(6):586-99. doi: 10.1111/j.1751-486X.2007.00245.x.
3
Improvement in the Management of Dyslipidemia in a Clinical Practice Population at Very High Cardiovascular Risk. The COLIPAR Project.极高心血管风险临床实践人群血脂异常管理的改善。COLIPAR项目。
Rev Esp Cardiol (Engl Ed). 2018 Nov;71(11):979-980. doi: 10.1016/j.rec.2017.07.015. Epub 2017 Oct 14.
4
Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.代谢综合征血脂异常的管理：超越他汀类药物治疗。
Metab Syndr Relat Disord. 2012 Jun;10(3):159-60. doi: 10.1089/met.2012.1500. Epub 2012 May 8.
5
Treating dyslipidemia: something more than giving statins.治疗血脂异常：不仅仅是使用他汀类药物。
Clin Investig Arterioscler. 2019 May-Jun;31(3):119-120. doi: 10.1016/j.arteri.2019.03.003. Epub 2019 Apr 20.
6
Fibrates consistently lower risk of cardiovascular events across high-risk groups.贝特类药物持续降低高危人群发生心血管事件的风险。
Cardiovasc J Afr. 2010 May-Jun;21(3):174.
7
Role of dyslipidemia in patients with chronic kidney disease.血脂异常在慢性肾脏病患者中的作用。
Postgrad Med. 2013 Jul;125(4):28-37. doi: 10.3810/pgm.2013.07.2676. Epub 2013 Jul 10.
8
[To improve cardiovascular health: we are forced for not loosing impulse].为改善心血管健康：我们不能失去动力。 （原英文句子语法有误，正确表达可能是To improve cardiovascular health, we are forced not to lose impulse ）
Clin Investig Arterioscler. 2016 Jan-Feb;28(1):43-6. doi: 10.1016/j.arteri.2015.10.001. Epub 2015 Nov 14.
9
Therapy and clinical trials.治疗与临床试验。
Curr Opin Lipidol. 2015 Oct;26(5):472-4. doi: 10.1097/MOL.0000000000000225.
10
Drug therapy of diabetic dyslipidemia: do the statins suffice?糖尿病血脂异常的药物治疗：他汀类药物足够吗？
Am J Ther. 2015 Jan-Feb;22(1):87-8. doi: 10.1097/MJT.0b013e318293b0f9.
本文引用的文献
1
Increased carotid intima-media thickness and stiffness in obese children.肥胖儿童的颈动脉内膜中层厚度增加及血管僵硬度增加。
Diabetes Care. 2004 Oct;27(10):2506-8. doi: 10.2337/diacare.27.10.2506.
2
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.52个国家中与心肌梗死相关的潜在可改变风险因素的影响（INTERHEART研究）：病例对照研究
Lancet. 2004;364(9438):937-52. doi: 10.1016/S0140-6736(04)17018-9.
3
Development and preliminary testing of a patient decision aid to assist pharmaceutical care in the prevention of cardiovascular disease.一种用于辅助药学服务预防心血管疾病的患者决策辅助工具的开发与初步测试。
Pharmacotherapy. 2004 Jul;24(7):909-22. doi: 10.1592/phco.24.9.909.36104.
4
Adherence with statin therapy in elderly patients with and without acute coronary syndromes.老年急性冠脉综合征患者与非急性冠脉综合征患者他汀类药物治疗的依从性
JAMA. 2002;288(4):462-7. doi: 10.1001/jama.288.4.462.
5
Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology.使用多危险因素评估方程评估心血管风险：美国心脏协会和美国心脏病学会给医疗专业人员的声明
Circulation. 1999 Sep 28;100(13):1481-92. doi: 10.1161/01.cir.100.13.1481.
6
Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?抗高脂血症药物的停药情况——临床试验报告的比率能反映初级保健机构中的比率吗？
N Engl J Med. 1995 Apr 27;332(17):1125-31. doi: 10.1056/NEJM199504273321703.
7
Coronary artery disease in Vietnam casualties.越南伤亡人员中的冠状动脉疾病
JAMA. 1971 Jul 26;217(4):478-9.
8
Coronary artery disease in combat casualties in Vietnam.越南战争中战斗伤亡人员的冠状动脉疾病
JAMA. 1971 May 17;216(7):1185-7.
9
Coronary artery atherosclerosis revisited in Korean war combat casualties.朝鲜战争战斗伤亡人员冠状动脉粥样硬化再探讨。
Arch Pathol Lab Med. 1987 Oct;111(10):972-6.
Zotero 插件